We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+1.86%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$54.7B
AUM Growth
+$1.45B
Cap. Flow
+$1.02B
Cap. Flow %
1.86%
Top 10 Hldgs %
17.33%
Holding
3,009
New
39
Increased
2,170
Reduced
725
Closed
55

Top Buys

Rank Stock Value
1
FIS icon
Fidelity National Information Services
FIS
+$65.3M
2
GPN icon
Global Payments
GPN
+$40.3M
3
MSFT icon
Microsoft
MSFT
+$37.9M
4
LHX icon
L3Harris
LHX
+$32.8M
5
AMZN icon
Amazon
AMZN
+$32.5M

Sector Composition

Rank Sector Weight
1 Technology 18.64%
2 Financials 15.56%
3 Healthcare 12.85%
4 Consumer Discretionary 10.31%
5 Industrials 10.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVID
2701
DELISTED
Avid Technology Inc
AVID
$228K ﹤0.01%
36,755
-175
-0.5% -$1.37K
PZN
2702
DELISTED
Pzena Investment Management, Inc. Class A
PZN
$227K ﹤0.01%
25,486
-275
-1% -$2.28K
UEC icon
2703
Uranium Energy
UEC
$5.32B
$226K ﹤0.01%
232,111
-1,775
-0.8% -$1.8K
DHX icon
2704
DHI Group
DHX
$179M
$225K ﹤0.01%
58,564
+7,831
+15% +$29.1K
RMTI icon
2705
Rockwell Medical
RMTI
$28.9M
$224K ﹤0.01%
737
+16
+2% +$4.92K
PBIP
2706
DELISTED
Prudential Bancorp, Inc.
PBIP
$224K ﹤0.01%
13,187
+1,062
+9% +$18.3K
DNTH icon
2707
Dianthus Therapeutics
DNTH
$6.16B
$223K ﹤0.01%
1,361
-13
-0.9% -$2.47K
ITI
2708
DELISTED
Iteris, Inc.
ITI
$223K ﹤0.01%
38,796
+4,500
+13% +$24.5K
CVM icon
2709
CEL-SCI Corp
CVM
$26.2M
$222K ﹤0.01%
828
+99
+14% +$23.2K
LE icon
2710
Lands' End
LE
$394M
$222K ﹤0.01%
19,534
+1,603
+9% +$16.9K
FPRX
2711
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$222K ﹤0.01%
57,190
+4,657
+9% +$25.6K
PLSE icon
2712
Pulse Biosciences
PLSE
$2.63B
$221K ﹤0.01%
14,329
-105
-0.7% -$1.36K
SSTI icon
2713
SoundThinking
SSTI
$101M
$221K ﹤0.01%
9,601
-15
-0.2% -$486
EIGR
2714
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$221K ﹤0.01%
719
+18
+3% +$5.85K
DGICA icon
2715
Donegal Group Class A
DGICA
$727M
$220K ﹤0.01%
15,028
+1,410
+10% +$20.5K
UBX
2716
DELISTED
Unity Biotechnology
UBX
$220K ﹤0.01%
3,610
+92
+3% +$6.51K
AXTI icon
2717
AXT Inc
AXTI
$4.49B
$219K ﹤0.01%
61,520
+5,786
+10% +$22.3K
CASI
2718
DELISTED
CASI Pharmaceuticals
CASI
$218K ﹤0.01%
6,539
+26
+0.4% +$835
ESQ icon
2719
Esquire Financial Holdings
ESQ
$1.14B
$218K ﹤0.01%
8,786
+570
+7% +$13.6K
PEBK icon
2720
Peoples Bancorp of North Carolina
PEBK
$231M
$218K ﹤0.01%
7,344
+500
+7% +$13.9K
AFI
2721
DELISTED
Armstrong Flooring, Inc.
AFI
$217K ﹤0.01%
33,954
+2,697
+9% +$21.1K
BOC icon
2722
Boston Omaha
BOC
$438M
$216K ﹤0.01%
10,895
+497
+5% +$10.6K
EML icon
2723
Eastern Company
EML
$147M
$216K ﹤0.01%
8,710
+672
+8% +$16.8K
FARM
2724
DELISTED
Farmer Brothers
FARM
$216K ﹤0.01%
16,681
+1,273
+8% +$18.4K
IDT icon
2725
IDT Corp
IDT
$1.64B
$215K ﹤0.01%
20,371
+600
+3% +$5.99K

Similar funds

RhumbLine Advisers's Q3 2019 Portfolio in Review

As of Q3 2019, RhumbLine Advisers held 3,009 positions worth $54.7B, up 2.7% from $53.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 3.1%. RhumbLine Advisers opened 39 new positions and exited 55, leaving the 3,009-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q3 2019 buy was Avantor: 187,780 shares worth $2.76M.
  • RhumbLine Advisers added most to Fidelity National Information Services in Q3 2019, an estimated $65.3M increase.
  • RhumbLine Advisers's biggest Q3 2019 reduction was Leidos, cutting an estimated $15M.
  • RhumbLine Advisers fully exited Anadarko Petroleum in Q3 2019, selling an estimated $64.3M.
  • RhumbLine Advisers's ten largest holdings make up 17% of its $54.7B portfolio in Q3 2019.
  • RhumbLine Advisers opened 39 new positions and closed 55 in Q3 2019.
  • RhumbLine Advisers's portfolio value rose 2.7% quarter-over-quarter to $54.7B.

Based on RhumbLine Advisers's 13F filing for Q3 2019, filed 23 Oct 2019.